Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Wave Life Sciences CEO to Participate in Analyst-led Fireside Chat at Jefferies London Healthcare Conference

Wave Life Sciences CEO Paul Bolno will speak at the Jefferies London Healthcare Conference on November 20, 2024.Quiver AI SummaryWave Life Sciences Ltd. announced that CEO Paul Bolno will participate in...

WVE : 14.76 (+3.51%)
Wave Life Sciences to Present at Jefferies London Healthcare Conference

WVE : 14.76 (+3.51%)
Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences: Q3 Earnings Snapshot

WVE : 14.76 (+3.51%)
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

WVE : 14.76 (+3.51%)
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

WVE : 14.76 (+3.51%)
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

WVE : 14.76 (+3.51%)
1 Brand-New Big Reason to Buy This Biotech Stock Right Now

This stock currently has a good balance of risk and potential rewards.

WVE : 14.76 (+3.51%)
Wave Life Sciences Rockets 70% on Historic RNA Editing Success

Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases.

WFC : 75.04 (+1.98%)
WVE : 14.76 (+3.51%)
RJF : 163.41 (+0.76%)
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

WVE : 14.76 (+3.51%)
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

WVE : 14.76 (+3.51%)

Barchart Exclusives

3 Ways to Invest in Small-Cap Stocks Now
With small-cap stocks surging in response to Donald Trump's re-election and the Federal Reserve's rate cut, investors can tap into this momentum through three distinct ETFs: VBK, DWAS, and UWM, each offering a unique approach to capturing the growth potential of small-cap stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar